(Q45137898)

9 December 2017

0 references

BMS-927711 for the acute treatment of migraine (English)

1 reference

9 December 2017

1 reference

Marcelo E Bigal

1 reference

9 December 2017

language of work or name

English

0 references

publication date

13 August 2013

1 reference

9 December 2017

1 reference

9 December 2017

1 reference

9 December 2017

1 reference

9 December 2017

page(s)

90-92

1 reference

Possible sites of action of the new calcitonin gene-related peptide receptor antagonists

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Extracerebral manifestations in migraine. A peptidergic involvement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Emerging target-based paradigms to prevent and treat migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Excellent Tolerability But Relatively Low Initial Clinical Efficacy of Telcagepant in Migraine: A Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102413500728

21 January 2018

Identifiers

DOI

10.1177/0333102413500728

1 reference

9 December 2017

1 reference